Skip to content

Dr. Emily Park

Senior Associate, DCVC Bio

Emily works to unlock later-stage value in early-stage ther­a­peu­tics platform and compu­ta­tional biology companies, with a focus on strategic pipeline and drug development. She also provides strategic and operational guidance and fundraising support to DCVC Bio’s portfolio companies, empowering them to reach key milestones and realize their complete growth potential. 

Prior to joining DCVC Bio, Emily worked in the public markets, as a biotech equities analyst at Point72 Asset Management and on the Global Investment Research team at Goldman Sachs, where she conducted deep-dive analyses on early-stage ther­a­peu­tics and clinical trial catalysts across multiple disease areas for SMID-Cap biotech and pharma stocks. She has also done independent consulting for hedge funds and TechBio companies, where she has worked with executive teams on business development and capital fundraising. Emily received a bachelor’s degree in English literature from Columbia University and an MD from Rutgers New Jersey Medical School.